Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome

@article{Ariceta2009GuidelineFT,
  title={Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome},
  author={Gema Ariceta and Nesrin Beşbaş and Sally Ann Johnson and Diana Karpman and Daniel Landau and Christoph Licht and Chantal Loirat and Carmine Pecoraro and C. Mark Taylor and Nicole Kar and Johan VandeWalle and Lothar Bernd Zimmerhackl and The European Paediatric Study Group for Hus},
  journal={Pediatric Nephrology},
  year={2009},
  volume={24},
  pages={687-696}
}
This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific diagnostic sub-groups of HUS. HUS in children is mostly due to infection, enterohemorrhagic Escherichia coli (EHEC), Shigella dysenteriae type 1 in some geographic regions, and invasive Streptococcus pneumoniae. These sub-groups are relatively… Expand
Hemolytic uremic syndrome in children~-- a concise review
TLDR
This review provides a comprehensive overview of the existing literature on the epidemiology, etiology, pathogenesis, clinical presentation, diagnosi s and management of HUS. Expand
Hemolytic uremic syndrome.
TLDR
Supportive care remains the cornerstone of management of HUS and efforts should be made to make an exact etiological diagnosis in all patients, as long-term treatment and prognosis is affected. Expand
A time for reappraisal of “atypical” hemolytic uremic syndrome: should all patients be treated the same?
TLDR
Given the heterogeneous nature and variable prognosis of atypical HUS, treatment should be carefully considered prior to the use of long-term plasma therapy and/or eculizumab. Expand
Management of hemolytic uremic syndrome
TLDR
The current understanding of the pathogenesis of HUS is reviewed and how this has led to advances in patient care is reviewed to improve outcomes in patients with atypical forms of H US. Expand
Atypical hemolytic uremic syndrome: a clinical conundrum
TLDR
A single-center retrospective review of HUS patients from 2003 to 2012 does not show poorer outcomes in STEC− HUS, and the cost-effectiveness of genetic testing, eculizumab, and plasmapheresis in ST EC− H US need to be evaluated further. Expand
Hemolytic uremic syndrome in a developing country: Consensus guidelines
TLDR
Limited diagnostic capabilities and lack of access to eculizumab prevent the implementation of international guidelines for HUS in most developing countries, and practice guidelines for India are proposed. Expand
Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
TLDR
Clinical cases where eculizumab use was probably not appropriate once the correct diagnosis of typical HUS was made and cases where it would have been useful because of the late diagnosis of aHUS are reported. Expand
A new era in hemolytic uremic syndrome. Diagnosis and treatment of a rare disease
TLDR
The serological anti-O157 LPS assay clearly makes a positive contribution when used in combination with standard fecal diagnostic tests to diagnose STEC-HUS and should be incorporated in clinical practice. Expand
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome
TLDR
This audit provides a snapshot of the early outcome of a group of children with aHUS in the months prior to more widespread use of eculizumab. Expand
Management of hemolytic-uremic syndrome in children
  • S. Grisaru
  • Medicine
  • International journal of nephrology and renovascular disease
  • 2014
TLDR
This review provides a summary of the current knowledge on the epidemiology, pathophysiology, and clinical presentation of childhood HUS, focusing on a practical approach to best management measures. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Where next with atypical hemolytic uremic syndrome?
TLDR
A comprehensive diagnostic approach is indicated for aHUS based on the latest knowledge on complement dysregulation to gain both immediate and future patient benefit by assisting in choosing more appropriate therapy for each patient. Expand
Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood.
TLDR
It appears that with the introduction of plasma exchange there has been an improved outcome in the initial phase, but the survivors tend to have relapses. Expand
Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?
TLDR
The data demonstrate the necessity of considering genetic changes of the pathogen during infection to adapt appropriately diagnostic strategies and hamper epidemiological investigations and lead to inappropriate clinical management. Expand
Challenges in the management of infantile factor H associated hemolytic uremic syndrome
TLDR
The recurrent HUS responded to plasma infusions and renal function improved from a glomerular filtration rate of 21 to 50 ml/min per 1.73 m2, and the infusions of fresh-frozen plasma were necessary at once-weekly intervals at a dose of 40–45 ML/kg in order to maintain remission and resulted in significant hyperproteinemia. Expand
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.
TLDR
A classification that accommodates both a current understanding of causation and clinical association in cases for whom cause of disease is unclear is proposed and is expected to increase the proportion of cases in whom a level 1 etiological diagnosis is confirmed. Expand
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias
TLDR
These guidelines attempt to define the various clinical subtypes, specify the recognized diagnostic features and look critically at management options for TTP patients. Expand
Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate
TLDR
A case of neonatal-onset aHUS associated with complete FH deficiency due to novel compound heterozygous mutations in the HF1 gene is reported, which was rapidly followed by the development of micro-angiopathic hemolytic anemia. Expand
Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection.
TLDR
Two patients with HUS in whom no E coli O157:H7 was demonstrable in stool cultures are described, illustrating the need to investigate patients with nondiarrheal HUS for infection with Shiga toxin-producing E coli of the non-O157 strain variety. Expand
Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment.
  • J. Davin, K. H. Olie, +6 authors T. Goodship
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2006
TLDR
The response to treatment of these monozygotic female twins with factor H-related atypical hemolytic uremic syndrome suggests that long-term PE may have benefits over plasma infusion alone. Expand
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.
TLDR
It is supported for the first time that HUS may occur in a context of an autoimmune disease with the development of anti-FH-specific antibody leading to an acquired FH deficiency, which may lead to the design of new approaches of diagnosis and treatment in plasma exchanges or immunosuppressive therapies. Expand
...
1
2
3
4
...